RxDoctor Payments Data

Emily Willmann

Primary Care · Thornton, CONPI 1467020644

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,815 of the $4,320 with a category attached, or 88.3%. It is spread thinly across 44 manufacturers, the largest accounting for just 8.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,746, more than ten times the $53 reported in 2022. Among primary care clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,320in general payments, 2019–2025

Across 164 payments — averaging $26.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$386
  • Johnson & Johnson$369
  • Novartis$317
  • Incyte Corporation$208
  • Genentech USA, Inc.$202
  • Tersera Therapeutics LLC$173
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$3,81588%
  • Education$50512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,320 in reported general payments places this provider in the 95th percentile of 112 primary care providers in Colorado.

See all primary care providers in Colorado

Medicare billing

Part B allowed, 2024
$37,660
Medicare patients
240
Services billed
939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib18$284,476
JakafiRuxolitinib Phosphate11$189,602
VenclextaVenetoclax13$28,716
XareltoRivaroxaban21$17,270
EliquisApixaban15$8,276
TrexallMethotrexate Sodium11$3,618
Enoxaparin Sodium11$1,997
Oxycodone Hcl36$1,344
Ondansetron OdtOndansetron47$1,224
Prochlorperazine Maleate51$1,172
Letrozole27$688
Dexamethasone22$620
Hydroxyurea29$547
Olanzapine27$364
Morphine Sulfate ErMorphine Sulfate12$298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$208$189,60211 claims
AbbVieVenclexta$124$28,71613 claims
Johnson & JohnsonXarelto$369$17,27021 claims
PfizerEliquis$146$8,27615 claims
Lilly USA, LLCOlanzapine$55$36427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 primary care providers in Colorado.

Other primary care in Thornton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →